Sanofi runs emotive RSV campaign zeroing in on a baby’s bronchiolitis breathing sounds
Would you know the difference between a normal cold and one that has turned into something more serious? | Would you know the ...
Model output · Signal date 2026-11-11
Sanofi (SNY) Stock Forecast Nov. 11, 2026
Analysis updated on Nov. 11, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
of 4226 stocks scored
Rank correlation · 90D
15.0%
Spearman, 358 dates
Market Cap
$118.90B
large-cap · #12 of 60 peers
Summary
Sanofi (SNY) stock forecast summary
Our AI scores Sanofi every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Sanofi is a large-cap company with a market capitalization of $118.90B. It ranks number 12 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For SNY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 15.0%, measured on 358 forecast dates between 2022-08-24 and 2026-08-13 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-08-24 and 2026-10-12. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +6.5%, buy ≥ +4.4%, sell < +2.2%, strong sell < +0.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-11 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SNY included.
Price
SNY price chart and AI forecast
Cross-section · 2026-11-11
How SNY ranks among 4226 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2025-12-31
Sanofi (SNY) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric. Statement values were filed in EUR and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
Valuation & Market
| Metric | SNY | Rank |
|---|---|---|
| Market Cap | $118.90B | 12/60 |
Profitability & Margins
| Metric | SNY | Rank |
|---|---|---|
| ROE | 30.0% | 9/39 |
| ROA | 16.9% | 8/43 |
| ROIC | 20.7% | 7/46 |
Financial Health
| Metric | SNY | Rank |
|---|---|---|
| Current Ratio | 1.09x | 50/58 |
| Quick Ratio | 0.73x | 40/43 |
| Financial Leverage | 1.78x | 27/47 |
| Working Capital | $3.06B | 13/58 |
Cash Flow
| Metric | SNY | Rank |
|---|---|---|
| Operating Cash Flow | $28.11B | 6/60 |
| OCF Growth YoY | -11.9% | 25/34 |
Operational Efficiency
| Metric | SNY | Rank |
|---|---|---|
| Inventory Turnover | 3.8x | 7/34 |
| Days Inventory | 96 days | 28/34 |
Income Statement
| Metric | SNY | Rank |
|---|---|---|
| Operating Income | $23.11B | 5/52 |
| Net Income | $24.28B | 3/47 |
| R&D Expense | $25.35B | 5/59 |
| SG&A Expense | $32.28B | 4/41 |
| Cost of Goods Sold | $44.17B | 2/36 |
Dividend & Shareholder Information
| Metric | SNY | Rank |
|---|---|---|
| Shares Outstanding | 2465M | – |
| Net Income Growth | 5.1% | 12/23 |
Balance Sheet Highlights (USD millions, converted from EUR)
| Total Current Assets | $36.36B | 24.4% of assets |
| Cash & Short-term Investments | $8.99B | 6.0% of assets |
| Inventory | $12.00B | 8.1% of assets |
Quarterly Financial Reports
SNY quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Sanofi (SNY) industry peers
Companies classified under the same SEC industry code as Sanofi (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| SNY Sanofi | $118.90B | |
| LLY Eli Lilly & Co | $1.35T | |
| JNJ Johnson & Johnson | $675.92B | |
| ABBV Abbvie Inc. | $519.34B | |
| MRK Merck & Co., Inc. | $365.26B | |
| NVS Novartis Ag | $311.52B | |
| AZN Astrazeneca Plc | $289.48B | |
| ABT Abbott Laboratories | $192.07B | |
| NVO Novo Nordisk A S | $180.87B | |
| PFE Pfizer Inc | $167.34B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $138.87B | |
| BMY Bristol Myers Squibb Co | $128.37B | |
| GSK Gsk Plc | $103.35B | |
| REGN Regeneron Pharmaceuticals, Inc. | $94.31B | |
| TAK Takeda Pharmaceutical Co Ltd | $65.38B | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.41B | |
| ONC Beone Medicines Ltd. | $48.20B | |
| GMAB Genmab A/S | $34.78B | |
| ZTS Zoetis Inc. | $34.07B | |
| ROIV Roivant Sciences Ltd. | $29.75B | |
| RPRX Royalty Pharma Plc | $29.74B | |
| INSM Insmed Inc | $26.21B | |
| UTHR United Therapeutics Corp | $25.25B | |
| VTRS Viatris Inc | $23.95B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.31B | |
| ASND Ascendis Pharma A/S | $16.85B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.93B | |
| BBIO Bridgebio Pharma, Inc. | $15.32B | |
| SMMT Summit Therapeutics Inc. | $14.22B | |
| ELAN Elanco Animal Health Inc | $13.37B | |
| RDY Dr Reddys Laboratories Ltd | $12.40B | |
| BMRN Biomarin Pharmaceutical Inc | $11.06B | |
| TGTX Tg Therapeutics, Inc. | $10.20B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.99B | |
| PRAX Praxis Precision Medicines, Inc. | $9.43B | |
| SYRE Spyre Therapeutics, Inc. | $9.21B | |
| PTGX Protagonist Therapeutics, Inc | $8.82B | |
| CORT Corcept Therapeutics Inc | $7.93B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.85B | |
| CYTK Cytokinetics Inc | $7.81B | |
| ALKS Alkermes Plc. | $7.80B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.47B | |
| AXSM Axsome Therapeutics, Inc. | $7.38B | |
| ORKA Oruka Therapeutics, Inc. | $7.25B | |
| ABVX Abivax S.A. | $7.07B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.92B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.83B | |
| LGND Ligand Pharmaceuticals Inc | $6.28B | |
| MANE Veradermics, Inc | $6.20B | |
| BLTE Belite Bio, Inc | $6.16B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.13B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| COGT Cogent Biosciences, Inc. | $5.49B | |
| ERAS Erasca, Inc. | $5.41B | |
| PTCT Ptc Therapeutics, Inc. | $5.36B | |
| EWTX Edgewise Therapeutics, Inc. | $5.05B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.97B | |
| IONS Ionis Pharmaceuticals Inc | $4.68B | |
| TVTX Travere Therapeutics, Inc. | $4.65B | |
| LQDA Liquidia Corp | $4.60B |
Where SNY sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Sanofi (SNY) stock news
Sanofi stops development of Nurix-partnered immune drug
The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a ...
Sanofi Takes €4.7b Statutory Profit Hit on Unusual Items
Sanofi took a €4.7b statutory profit hit from unusual items in the last twelve months, even as the market liked the latest ...
FAQ
Sanofi (SNY) stock forecast FAQ
What is the Sanofi (SNY) stock forecast?
Our AI scores Sanofi every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Sanofi stock predictions?
For SNY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 15.0%, measured on 358 forecast dates between 2022-08-24 and 2026-08-13 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-08-24 and 2026-10-12. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Sanofi forecasts updated?
Sanofi forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 11, 2026.
Which companies are Sanofi's industry peers?
60 issuers in our coverage, SNY included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.